About this trial
ICU survivors are at an increased risk of hospital and ICU readmission. Among the complications of ICU stay, diaphragmatic dysfunction is common, with a prevalence of 60 to 80%, and is associated with increased mortality and prolonged hospital stays. Furthermore, several studies have reported that the observation of impaired respiratory muscle function upon ICU discharge is associated with a poor long-term prognosis. However, the incidence and prognostic impact of persistent diaphragmatic dysfunction at ICU discharge have never been evaluated. The measurement of dyspnea, a composite evaluation of respiratory muscle function, has not been assessed for predicting prognosis upon ICU discharge.
The hypothesis of the project is that the presence of ICU-acquired diaphragmatic dysfunction at ICU discharge is associated with a poorer prognosis within 90 days.
Eligibility criteria
Qualifiers
Age ≥ 18 years
Invasive or non-invasive respiratory support (ventilation, high-flow oxygen therapy, whatever the reason) for at least 48 hours.
Weaning from respiratory support (invasive or not) within the last 24 hours.
Patient (or trusted person/relative) informed and not opposed to the study.
Disqualifiers
Known pre-existing diaphragmatic dysfunction (phrenic lesion, neuromuscular disease, etc.)
Patients with tracheostomy
Non-communicating patients
Patients deprived of liberty by court or administrative order, or under legal protection (guardianship, curators).
Trial design
Treatments tested in this trial
- Diaphragmatic ultrasound and data collection